A clinically proven formula that works like a prebiotic, probiotic, symbiotic, and postbiotic all in one to support microbiome and gut health.
- The only formula that has unique probiotics as well as supporting strains to increase colonization and effectiveness, and naturally produces short chain fatty acids like butyrate and propionate!
- Reduces the growth of pathogenic bacteria while promoting the growth of beneficial bacteria like Bifidobacterium and akkermansia.
- Normalizes the inflammatory response, promotes detoxification, supports immunity and provides relief from allergies
- Proven to help prevent traveler’s and antibiotic-induced diarrhea
- The only probiotic in Canada that includes a strain which produces clinical amounts of butyric acid.
$53.06 — or subscribe and save 20%
The gut microbiome is essential to normal health and well-being all over the body. Probiotic-3 is a unique synergistic probiotic formula that contains three bacterial species with specific health-promoting attributes: Enterococcus faecium T-110, Clostridium butyricum TO-A, and Bacillus subtilis TO-A. While these three strains are newer to the North American market, they have been widely used in hospitals and pharmacies throughout Asia since the early 1960’s.
C.butyricum TO-A is a natural resident of the human gastrointestinal tract. It breaks down dietary fibre into short-chain fatty acids (SCFAs); butyrate, propionate and acetate. The benefits of these SCFAs include reduced inflammation, protection against intestinal damage,1 thereby preventing “leaky gut” syndrome, improved insulin resistance and immune support.2 E. faecium T-110 is a natural resident of the human gastrointestinal tract that works with C. butyricum to create a balanced microbiome. It produces lactic acid, which reduces the gastrointestinal pH, thus preventing the growth of harmful bacteria.3 It has also been shown to reduce the severity of acute diarrhea. B. subtilis TO-A is a prebiotic that supports the growth of E. faecium and C. butyricum, to increase their growth by 10 times.
Clinical studies have shown wide-ranging health benefits including allergy reduction,4-6 improved immunity, reduced bloating, constipation and diarrhea, positive effects on cognition, depression, anxiety and even enhanced detoxification. Additionally, Probiotic-3 is the only probiotic product in Canada that contains a strain of bacteria from the Clostridium family, which has been shown to have antagonistic effects against several pathogenic bacteria such as C. difficile, H. pylori, and E. coli.
Probiotic-3’s unique symbiotic formula combines three human strains that have been clinically studied in more than 40 human studies. It is stable at room temperature and is highly resistant to bile and gastric acids. Additionally, this formula has 60 years of use in hospitals and pharmacies throughout Asia. Each strain was carefully chosen to ensure synergy and safety with the others.
- Glocker E-O, Kotlarz D, Boztug K, et al. Inflammatory Bowel Disease and Mutations Affecting the Interleukin-10 Receptor. N Engl J Med. 2009;361(21):2033-2045. doi:10.1056/NEJMoa0907206.
- Hayashi A, Sato T, Kamada N, et al. A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice. Cell Host Microbe. 2013;13(6):711-722. doi:10.1016/j.chom.2013.05.013.
- Takahashi M, Taguchi H, Yamaguchi H, Osaki T, Kamiya S. Studies of the effect of Clostridium butyricum on Helicobacter pylori in several test models including gnotobiotic mice. J Med Microbiol. 2000;49(7):635-642. doi:10.1099/0022-1317-49-7-635.
- Zhang J, Su H, Li Q, et al. Oral administration ofClostridium butyricumCGMCC0313-1 inhibits β-lactoglobulin-induced intestinal anaphylaxis in a mouse model of food allergy. Gut Pathog. 2017;9:11. doi:10.1186/s13099-017-0160-6.
- Bin Lan B, Yang F, Lu D, Lin Z. Specific immunotherapy plus Clostridium butyricum alleviates ulcerative colitis in patients with food allergy. Sci Rep. 2016;6(1):25587. doi:10.1038/srep25587.
- Cai M, Zeng L, Li L-J, et al. Specific immunotherapy ameliorates ulcerative colitis. Allergy, Asthma Clin Immunol. 2016;12(1):37. doi:10.1186/s13223-016-0142-0.
Probiotic-3 contains a synergistic blend of probiotic strains that has been well studied and used in Japan for over 60 years. Probiotic-3 helps support gastrointestinal health and promotes the growth of healthy gut flora while inhibiting harmful gut bacteria.
AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, corn, nuts, peanuts, sesame seeds, sulphites, mustard, soy, eggs, fish, or shellfish.
Take two to three capsules daily with/without food, or as directed by a qualified health care practitioner. Take at least two to three hours before or after taking antibiotics.
Consult a health care practitioner prior to use if you are pregnant or breastfeeding, if you have fever, vomiting, bloody diarrhea, or severe abdominal pain. Do not use if you have an immune compromised condition (e.g. AIDS, lymphoma, patients undergoing long-term corticosteroid treatment). If symptoms of digestive upset (e.g. diarrhea) occur, worsen or persist beyond three days, discontinue use and consult a health care practitioner. This product contains lactose, dextrin, and potato starch, do not use if you have such allergies.
The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.
Treatment of Ulcerative Colitis
A single-arm pilot study was designed to evaluate the effect of Probiotic-3 against symptoms associated with treatment-refractory ulcerative colitis. Twenty patients with mild to moderate colitis took three Probiotic-3 capsules, three times a day, for four weeks. The primary outcome measure was resolution of symptoms. In total, 45% of patients exhibited complete remission, with 10% showing partial remission. Analysis of their colonic microbiota showed that populations of Bifidobacteria increased significantly in most patients. Furthermore, this positive response was associated with a normalization of intestinal populations of other commensal bacteria.
Tsuda Y, Yoshimatsu Y, Aoki H, et al. Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy. Scand J Gastroenterol. 2007;42(11):1306-1311. doi:10.1080/00365520701396091
A subsequent randomized, placebo-controlled trial evaluated the use of Probiotic-3 to maintain remission, in ulcerative colitis patients previously treated with the standard of care. Here, 46 patients were randomized to receive three Probiotic-3 tablets twice a day, or placebo, for 12 months. The primary outcome measure was incidence of relapse. There were 50% fewer relapses in the Probiotic-3 group than in the control group.
Yoshimatsu Y, Yamada A, Furukawa R, et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World J Gastroenterol. 2015;21(19):5985-5994. doi:10.3748/wjg.v21.i19.5985
A randomized, double-blind, placebo-controlled trial was designed to test the ability of Probiotic-3 to reduce symptoms associated with acute infectious diarrhea. The study focused on 304 children between three months and six years of age admitted to a primary care centre with viral or bacterial infections. The primary outcome measure was the duration of diarrhea. The children either received a daily dose of Probiotic-3 for seven days, or a placebo. Duration of diarrhea was 30% shorter in children receiving Probiotic-3, and was associated with a 30% shorter hospital stay. Probiotic-3-supplemented children had elevated stool counts of Bifidobacteria, increased production of the tolerogenic IL-10 cytokine, and decreased production of the inflammatory TNFα cytokine.
Chen CJCC, Kong MS, Lai MW, et al. Probiotics have clinical, microbiologic, and immunologic efficacy in acute infectious diarrhea. Pediatr Infect Dis J. 2010;29(2):135-138. doi:10.1097/ INF.0b013e3181b530bf
The standard of care to resolve Helicobacter pylori infections involves administration of a proton pump inhibitor along with an antibiotic cocktail. However, this failed to clear the infection in about a third of patients. In a clinical study designed to assess the effect of Probiotic-3 supplementation on H. pylori clearance, 182 patients were randomized to standard of care supplemented with daily Probiotic-3, or to standard of care alone, for 14 days. The clearance rate with Probiotic-3 supplementation was 84%, as compared to 63% for standard therapy.
No studies have directly assessed the extent of intestinal colonization by the bacteria in Probiotic-3; however, it is possible to use various biomarkers to obtain similar information. In a clinical study in which participants received daily Probiotic-three capsules for seven days, stool samples were collected on days two, four, and seven for bacteriological analyses. Bifidobacteria and Lactobacilli counts were significantly elevated by day seven. Production of TNFα by patient peripheral blood mononuclear cells was reduced by day two, and IL-10 production was elevated by day six. This data suggests a two to seven-day timeline to action for Probiotic-3 supplementation.
Chen CJCC, Kong MS, Lai MW, et al. Probiotics have clinical, microbiologic, and immunologic efficacy in acute infectious diarrhea. Pediatr Infect Dis J. 2010;29(2):135-138. doi:10.1097/ INF.0b013e3181b530bf.